HSANZ Leadership

Dr Adam Bryant

Adam Bryant is a Senior Staff Specialist at Liverpool Hospital where he has worked since 2012 as a development member of the allogeneic BMT program which commenced at this time. Adam’s other specific subspecialty interest is as a core member of the Liverpool Hospital Myeloma Subspecialty Unit. Adam and his colleagues are responsible for an exceptionally large practice of myeloma patients. This unit has been a strong recruiter for many Phase 2 and 3 clinical studies of myeloma therapies. Adam has been the Principle Investigator of several myeloma trials and is an active member of the Australia Leukaemia and Lymphoma Group Myeloma Working Party.
His major other role is as Chair of the rapidly expanding Haematology Clinical Trials Unit of South Western Sydney that aims to bring new and innovative therapies to the patients of this previously underserviced region. Adam has also had various roles with the NSW Cancer Institute, in particular as the Chair of the EviQ Haematology Reference Committee.  

A/Prof Andrea Henden

A/Prof Andrea Henden (BSc MBBS (Hons) FRACP FRCPA PhD) is a clinical Haematologist and Bone Marrow Transplant physician at the Royal Brisbane and Women's Hospital in Brisbane, Australia and a holder of a Metro North Clinician Research Fellowship. She has a clinical interest in transplantation and cellular therapies, and the infectious complications of these treatments. A/Prof Henden is also a research officer in the Translational Cancer Immunotherapy Laboratory at QIMR Berghofer Medical Research Institute. Her research focusses on transplant immunology and current active projects include cellular therapies for infection, and the role of the microbiome and metabolism on T cell function in the context of transplantation and cellular therapy. She is the Principal Investigator on a number of Investigator Initiated Clinical Trials bringing novel immunotherapies to the clinic, with a focus toward treating complications of immunotherapies.   

Dr Sumi Ratnasingam (AdvDipMedSci, BMedSci, MBBS, FRACP, FRCPA, GCertCncrSc) is a clinical haematologist at The Alfred Hospital, specialising in lymphoma and CAR-T cell therapy. She also practices at Epworth HealthCare, balancing the demands of public and private practice.
Sumi spent more than a decade at University Hospital Geelong, providing comprehensive haematology care across the Barwon region and Bellarine Peninsula. This experience reinforced her commitment to ensuring regional patients have equitable access to world-class therapies. During this time, she also served as a senior lecturer at Deakin University and held several leadership roles within the hospital.
Her work extends beyond clinical care, with active involvement in research and clinical trials. She has been a principal investigator on multiple national and international lymphoma studies and regularly contributes to publications through the Australasian Lymphoma Alliance (ALA) and Australasian Leukaemia & Lymphoma Group (ALLG). She is currently Medical Secretary for the ALLG Lymphoma Scientific Working Party.
Dedicated to education and governance, Sumi mentors future physicians and haematologists, serves on the Committee for Joint College Training (CJCT), and the Central Appointments Process for Haematology Advanced Training (CAPHAT), as a HSANZ representative.
Sumi remains committed to advancing innovative therapies and improving outcomes for patients with blood cancers through her clinical practice, research, and advocacy.  

Dr Nicole Wong Doo

Dr Nicole Wong Doo (MBBS (Hons), PhD, FRACP, FRCPA, GradCert[ClinTch]) is a clinical and laboratory haematologist at Concord Repatriation General Hospital, senior lecturer at Concord Clinical School and Honorary Research Associate at the Cancer Council Victoria. As the Director of the Haematology Clinical Research Unit at Concord Hospital, she leads a team of 25 in the delivery of clinical trials embedded within clinical practice and clinical-translational research. Since completing a PhD in lymphoma and myeloma epigenetics at the University of Melbourne, she has built a growing portfolio of clinical research, as the Australian principal investigator of the ALLG HD13 RADAR trial in hodgkin lymphoma supported by the MRFF. She has ongoing research interests in lymphoma and multiple myeloma clinical trials and supportive care, including being a member of the ALLG Multiple Myeloma, Lymphoma and Supportive Care Scientific Working Parties, member of the Australasian Lymphoma Alliance and on the Steering Committee of the Australasian Myeloma Research Consortium. With a growing profile in patient-reported outcomes (PRO) research, she leads a PRO study in Oral therapy for Blood Diseases and is PI of a digital research project called MyHodgkin MyHealth, a mobile App for patient-entered health outcomes in Hodgkin lymphoma. Dr Wong Doo is dedicated to promoting excellence in Haematology in the Asia-Pacific region and works to deliver training and education as a member of the Royal College of Pathologists Australasia Pathology Education Outreach Committee (PEOC).  

Dr James Liang

Currently clinical and laboratory haematologist at Middlemore Hospital. After completing his medical degrees (BHBm MBChB) in 2005 from the University of Auckland, James continued his medical training in the Auckland region. In 2015 he was awarded a research fellowship from Cancer and Palliative Network (Perth, Australia) and spent 2016-2017 at the University of Western Australia and Sir Charles Gairdner Hospital. Since that time, he maintains special interest in adult haematological cancer especially in myeloproliferative neoplasm.  

A/Prof Cindy Lee

Associate Professor Cindy Lee is a clinical and laboratory haematologist at the Royal Adelaide and Queen Elizabeth Hospitals, where she is the co-lead of the myeloma program and leads a large portfolio of clinical trials. She trained in Perth (Australia), followed by an EBMT (European Group for Blood and Marrow Transplantation) fellowship in immunotherapies and targeted radiotherapy in Myeloma in the UK. She is a member of the Medical and Scientific Advisory Group (MSAG) for Myeloma Australia, International Myeloma Society, the writing committees for the Centre for International Blood and Marrow Transplant Registry (CIBMTR) and the Worldwide Network for Blood and Marrow Transplantation (WBMT), as well as the myeloma scientific working group for the Australasian Leukaemia and Lymphoma Group (ALLG).  

Dr Andrew Guirguis

Dr Andrew Guirguis is a Clinical Haematologist at Austin Health and a Clinical Lab Head at the Olivia Newton-John Cancer Research Institute in Melbourne, Victoria since 2024. His clinical and research interests focus on understanding and targeting drivers of pre-leukaemic myeloid neoplasms, including the myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and myeloproliferative neoplasms (MPN). A University of Melbourne graduate, Andrew holds dual fellowships with the Royal Australasian College of Physicians (RACP) and the Royal College of Pathologists of Australasia (RCPA). He completed haematology training at the Alfred Hospital and a PhD at the Australian Centre for Blood Diseases, earning the HSANZ Baikie Medal. His postdoctoral research includes fellowships under Professor Ben Ebert at the Dana-Farber Cancer Institute and Professor Mark Dawson at the Peter MacCallum Cancer Centre. Andrew serves on the Acute Leukaemia and Laboratory Science Working Parties within the Australasian Leukaemia and Lymphoma Group (ALLG). Outside of work, he enjoys traveling, long-distance running and playing the piano – though he admits the latter two are still works in progress.  

Dr Prudence (Pru) Smith

Pru Smith is a haematologist at Hobart Hospital.  

Dr Matthew (Matt) Wright

Matt Wright is a clinical and lab Haematologist from Fiona Stanley Hospital in Perth.
He completed training in Sydney before enjoying a transplant fellowship in Vancouver, and later a sabbatical in Cambridge focussed on MPN.
His clinical interests are myeloid neoplasms and allotransplant, and he is a passionate teacher of laboratory medicine. Matt is a national examiner for the RCPA and RACP, and enjoys travelling to teach in the Asia-pacific region.
In his spare time Matt likes ocean swimming and losing to his two boys at Golf.  

Dr Amanda Goh

Amanda brings extensive trainee advocacy experience through roles with the CJCT in Haematology, the RACP College Trainees’ Committee and Queensland Trainees Committee, alongside long‑standing involvement in HSANZ.

She is committed to strengthening connection, education and representation for trainees and early career haematologists, with a clear focus on engaging, educating and empowering the next generation.  

Ty Simpson is a pioneering Haematology Nurse Practitioner at The Alfred, leading Australia’s CAR-T cell therapy program and transforming cancer care.

He's known for his compassionate leadership, national impact on nursing education, and dedication to improving patient outcomes - especially in complex clinical trials. Ty was named 2025 Australian Nurse of the Year. 

Ty also leads a nurse-led network across Australia and New Zealand, upskilling regional teams and ensuring expert care continues beyond hospital walls. His work is reshaping how nurses lead, learn, and deliver cutting-edge treatment.  

Dr Jackie Yim

Jackie is the General Manager and Company Secretary of the Haematology Society of Australia and New Zealand. His experience spans frontline cancer care, health economics, research, governance, strategy and organisational leadership. This breadth enables him to connect clinical realities, evidence and organisational priorities to support sound decision-making and effective delivery.

He works closely with the HSANZ Council to guide the Society’s strategy and strengthen its governance and operations, with a focus on supporting the haematology workforce and advancing education, advocacy and partnerships.

Jackie holds a PhD in Health Economics, an MBA and is a Graduate of the Australian Institute of Company Directors. He is committed to translating strategy into practical outcomes that strengthen HSANZ’s impact, sustainability and value to members across Australia and New Zealand.